CNS Drugs

, Volume 4, Supplement 1, pp 39–48 | Cite as


Clinical Profile
  • J. M. A. Sitsen
  • M. Zivkov


Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action, which has recently been registered in a number of European countries. Worldwide, to date, up to 2800 patients have been treated with mirtazapine, and its antidepressant efficacy was confirmed in a series of double-blind randomised clinical studies performed in hospitalised patients and outpatients in Europe and the USA. The results consistently showed that mirtazapine demonstrated superior efficacy when compared with placebo, and equal efficacy when compared with amitriptyline. A meta-analysis of amitriptyline-controlled studies involving patients with severe depression shows that mirtazapine is as effective as the tricyclic agent in this group of patients. Mirtazapine is well tolerated, with transient sedation and bodyweight gain reported in a limited number of patients.

Thus, with its unique mode of action, established efficacy, and good tolerability profile, mirtazapine represents a valuable addition to the available options for treating patients with depression.


Amitriptyline Mirtazapine Trazodone Hamilton Depression Rate Scale Brief Psychiatric Rate Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron® tablets after single and multiple dosing. Hum Psychopharmacol. In pressGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., Washington DC, 1980Google Scholar
  3. 3.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62PubMedCrossRefGoogle Scholar
  4. 4.
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRefGoogle Scholar
  5. 5.
    Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71PubMedCrossRefGoogle Scholar
  6. 6.
    Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63–70PubMedCrossRefGoogle Scholar
  7. 7.
    Overall JE, Gorcham DR. The brief psychiatric rating scale (BPRS). Psychol Reports 1962; 10: 799–812CrossRefGoogle Scholar
  8. 8.
    Guy W, editor. ECDEU assessment manual for psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338, National Institute for Mental Health, Rockville MD, 1976Google Scholar
  9. 9.
    Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–71PubMedCrossRefGoogle Scholar
  10. 10.
    Claghorn JI. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord. In pressGoogle Scholar
  11. 11.
    Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J Clin Psychiatry. In pressGoogle Scholar
  12. 12.
    Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191–6PubMedGoogle Scholar
  13. 13.
    Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994; 4: 145–50PubMedCrossRefGoogle Scholar
  14. 14.
    Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994; 4: 282CrossRefGoogle Scholar
  15. 15.
    Zivkov M, de Jongh GD. Org 3770 vs amitriptyline: a 6-week randomised double-blind multicentre trial in hospitalised patients. Human Psychopharmacol. In pressGoogle Scholar
  16. 16.
    Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol. In pressGoogle Scholar
  17. 17.
    Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled, efficacy and safety study of Org 3770. Hum Psycopharmacol. In pressGoogle Scholar
  18. 18.
    Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of Org 3770 and doxepin in patients with major depression. Eur Neuropsychopharmacol. In pressGoogle Scholar
  19. 19.
    van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone. A controlled study in hospitalised patients with major depression. Int Clin Psychopharmacol 1995; 10: 3–9PubMedCrossRefGoogle Scholar
  20. 20.
    Bowen RC, Kohout J. The relationship between agoraphobia and primary affective disorder. Can J Psychiatry 1979; 24: 317–22Google Scholar
  21. 21.
    Fawcett J, Crawitz HM. Anxiety symptoms and their relation to depressive illness. J Clin Psychiatry 1983; 44: 8–11PubMedGoogle Scholar
  22. 22.
    Hiller W, Zaudig M, Van Bose J. The overlap between depression and anxiety on different levels of psychopathology. J Affect Disord 1989; 16: 223–31PubMedCrossRefGoogle Scholar
  23. 23.
    Hamilton M. Mood disorders: clinical features. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry V. Baltimore: Williams and Wilkins, 1989: 892–913Google Scholar
  24. 24.
    American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993; 150 Suppl. 4: 1–26Google Scholar
  25. 25.
    Prien RF. Long-term treatment of affective disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1051–8Google Scholar
  26. 26.
    Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52Suppl. 5: 28–34PubMedGoogle Scholar
  27. 27.
    Bech P, Allerup P, Reisby N, et al. Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology 1984; 84: 276–81PubMedCrossRefGoogle Scholar
  28. 28.
    World Health Organization. Adverse reactions terminology (WHO-ART), version 1989: 28Google Scholar
  29. 29.
    Heimpel H. Drug induced agranulocytosis. Med Toxicol 1988; 3: 165–72Google Scholar
  30. 30.
    Clifford Lane H, Fauci AS. Sjögren’s syndrome. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991: 1449–50Google Scholar
  31. 31.
    Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam. Pharmacol Toxicol 1989; 65: 81–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • J. M. A. Sitsen
    • 1
  • M. Zivkov
    • 2
  1. 1.Medical Research and Development UnitN.V. OrganonOssThe Netherlands
  2. 2.Medical Services DepartmentN.V. OrganonOssThe Netherlands

Personalised recommendations